RT Journal Article SR Electronic T1 Validation of Several SUV-Based Parameters Derived from 18F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1202 OP 1208 DO 10.2967/jnumed.112.116426 VO 54 IS 8 A1 Wolfgang Peter Fendler A1 Donfack Beauclair Philippe Tiega A1 Harun Ilhan A1 Philipp M. Paprottka A1 Volker Heinemann A1 Tobias F. Jakobs A1 Peter Bartenstein A1 Marcus Hacker A1 Alexander Robert Haug YR 2013 UL http://jnm.snmjournals.org/content/54/8/1202.abstract AB 90Y radioembolization (selective internal radiation therapy [SIRT]) is a valuable therapeutic option for unresectable hepatic metastases arising from primary colorectal cancer. The present study evaluated the prognostic value of 18F-FDG PET/CT metabolic parameters for predicting survival after SIRT. Methods: Eighty patients with hepatic metastases of colorectal cancer were treated with SIRT. 18F-FDG PET/CT was performed at baseline and 3 mo after the treatment. Metabolic volume, total lesion glycolysis, and maximum and peak standardized uptake value (SUVmax and SUVpeak, respectively) according to PET Response Criteria in Solid Tumors (PERCIST 1.0) were obtained from 3 liver lesions in each patient, and the corresponding percentage changes from baseline to follow-up were calculated. Tumor response was defined as more than a 30% decrease in these parameters. Furthermore, response was evaluated in accordance with Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Toxicity events and survival were recorded. Results: Overall median survival after SIRT was 60 wk. Responders who had a change in metabolic volume or total lesion glycolysis had significantly longer survival (92 vs. 49 wk [P = 0.006] and 91 vs. 48 wk [P = 0.025], respectively). However, neither RECIST 1.1 criteria nor changes in SUVpeak or SUVmax after treatment predicted outcome (P = 0.086 for RECIST; P = 0.310 for change in SUVpeak; P = 0.155 for change in SUVmax). Conclusion: Changes in metabolic volume and total lesion glycolytic rate as measured by 18F-FDG PET predicted survival in patients with hepatic metastases from colorectal cancer, whereas changes in SUVpeak or SUVmax and RECIST 1.1 criteria did not predict survival.